GlaxoSmithKline plc has insisted it remains open to selling its Consumer Healthcare business after a major investor called into question the firm’s plan to spin-off and list the unit.
Activist hedge fund Elliott Management recently wrote to the UK-based pharma giant’s board of directors arguing that the sale of Consumer Healthcare, rather than GSK’s demerger
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?